The use of PSMA PET/CT to assist primary staging of prostate cancer (PCa) is characterized by a higher sensitivity for the detection of nodal and distant metastasis compared to conventional imaging [1–5]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.